Maravai LifeSciences Acquires Assets and Intellectual Property from Molecular Assemblies
Maravai LifeSciences, Inc. (
NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today its acquisition of intellectual property and relevant assets from Molecular Assemblies (MAI). The acquisition will expand Maravai and TriLink BioTechnologies' ability to enable customers to develop next-generation mRNA and CRISPR nucleic acid-based therapies.
Maravai LifeSciences Announces November 2024 Investor Conference ScheduleSAN DIEGO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (
NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in November.
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
Maravai LifeSciences, Inc. (
NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it has signed an agreement to acquire the DNA and RNA business of Officinae Bio. The acquisition is expected to expand Maravai and TriLink BioTechnologies' ability to assist customers in developing innovative nucleic acid-based therapies.
Maravai LifeSciences Reports Third Quarter 2024 Financial ResultsAnnounces Agreement to Acquire the DNA and RNA business of Officinae Bio, Advancing Support for Innovative Nucleic Acid R&D
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024SAN DIEGO, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (
NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2024 financial and operating results after the market closes on Thursday, November 7, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET.
TriLink BioTechnologies® & Alphazyme Collaborate to Launch New CleanScribe™ RNA Polymerase
TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces double-stranded RNA (dsRNA) in mRNA production. The new product reduces dsRNA by up to 85%, helping to develop safer, more potent mRNA therapeutics.
Cygnus Technologies and TriLink BioTechnologies® Collaborate to Launch AccuRes™ Host Cell DNA Quantification Kits
Cygnus Technologies (Cygnus), TriLink BioTechnologies (TriLink®), both part of Maravai LifeSciences (
NASDAQMRVI) have collaborated to launch Cygnus’ AccuRes™ Host Cell DNA Quantification Kits. Together, the companies have leveraged state-of-the-art technologies and reagents to develop an assay with unparalleled sensitivity and specificity to help produce safer, more stable biotherapeutics that surpass regulatory standards.
Maravai LifeSciences Announces August and September 2024 Investor Conference ScheduleSAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (
NASDAQMRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.
Maravai LifeSciences Reports Second Quarter 2024 Financial ResultsContinued Focus on Product Portfolio Expansion, Market Leadership and Scientific Innovation
Maravai LifeSciences Appoints Trey Martin to Board of DirectorsMaravai announces the appointment of CEO Trey Martin to its Board of Directors, highlighting his leadership, commitment to innovation, and industry experience
